British Peripheral Nerve Society

BPNS meeting 9 November 2018

Start Date

End Date

Friday 9 Nov 2018 10:00 AM

Friday 9 Nov 2018 17:00 PM

Location

Royal London Hospital, Whitechapel, London E1

Details

This meeting will be hosted by the Royal London Hospital (Queen Mary Innovation Centre, 5 Walden Street, London E1 2AF) The AGM will be held at the end. The local organiser is Dr Aleksandar Radunovic (Aleksandar.Radunovic@bartshealth.nhs.uk). The venue will be the Clark-Kennedy Lecture Theatre.

If you wish to attend the dinner in a restaurant after the meeting, please register and pay separately on the dinner page https://www.bpns.org.uk/event-details.aspx?Group=events&id=65

This will be an all-day meeting. The programme will include clinical case presentations and guest lectures from:

· Dr Luis Querol (Barcelona, Spain) – “CIDP: from phenotype to the paranode and back”.

· Giuseppe Lauria (Milan, Italy) – “Big pain, small fibres; personalising medicine in painful neuropathies”

· Ashwin Pinto (Southampton) on plasma exchange.

RCP CPD approval has been applied for. A certificate will be available at the end of the meeting.

A sandwich lunch and refreshments will be provided. If you have any dietary requirements please indicate special dietary requirements under 'special requests' in the registration form.

A BPNS Council meeting (for BPNS Council Members) will precede the meeting from 9.00 -10.00

The Annual General Meeting will be at 16.30 (BPNS members only).

We encourage registration in advance by clicking Book Tickets below. Members should log in to the BPNS website first to benefit from a reduced registration fee. Advance registration will close on 2 November 2018. Registration after this date is possible at the meeting but will incur a £10 surcharge. If you decide not to register in advance, please email secretariat@bpns.org.uk in advance to advise of your intention to attend so we know numbers for catering.

The deadline for abstract submission is Friday 12 October 2018. This has now passed so no more abstracts may be submitted.

The CSL Behring satellite symposium (initially planned for 8th November) has been postponed to next year.

Abstracts (can change before the event)

Title	Lead Author	Status
Hopping, Skipping, Jumping to Conclusions	Yann Shern Keh	Finished Version	View
Case study: Neuralgic amyotrophy following hepatitis E infection	Celia Shiles	Finished Version	View
The Distinguishing Investigative Features of a Nodo-Paranodopathy: Examining the notable findings in an antibody positive case	Neena Singh	Finished Version	View
A treatment-resistant demyelinating neuropathy	Rodney Walker	Finished Version	View
A cashier who can’t handle coins.	Chinar Osman	Finished Version	View
A recognisable, but variable phenotype of CMT2.	Carolynne Doherty	Finished Version	View
More than Holmes-Adie	Shiwen Koay	Finished Version	View
Upper Limb Predominance in Inherited Neuropathies	Grace McMacken	Finished Version	View
Beyond the checkpoint	Amy Gimson	Finished Version	View
The picture of excitement	Jane Pritchard	Finished Version	View
A very rare Case of a rapidLy progressive peripheraL neuropathy	janev fehmi	Finished Version	View

Programme

Time	Type		Presenter
09:15	Registration	Registration and coffee
10:00	Abstract	A recognisable, but variable phenotype of CMT2.	Dr Carolynne Doherty
10:15	Abstract	Upper Limb Predominance in Inherited Neuropathies	Dr Grace McMacken
10:30	Abstract	More than Holmes-Adie	Dr Shiwen Koay
10:45	Abstract	Beyond the checkpoint	Dr Amy Gimson
11:00	Refreshment	Coffee
11:25	Lecture	Big pain, small fibres; personalising medicine in painful neuropathies	Giuseppe Lauria
12:10	Abstract	A treatment-resistant demyelinating neuropathy	Dr Daniel Rudd
12:25	Abstract	A very rare Case of a rapidLy progressive peripheraL neuropathy	Dr janev fehmi
12:55	Refreshment	Lunch
13:45	Abstract	The Distinguishing Investigative Features of a Nodo-Paranodopathy: Examining the notable findings in an antibody positive case	Dr. Neena Singh
14:00	Abstract	Hopping, Skipping, Jumping to Conclusions	Dr Yann Shern Keh
14:15	Abstract	The picture of excitement	Dr Jane Pritchard
14:30	Lecture	CIDP: from phenotype to the paranode and back	Luis Querol
15:15	Refreshment	Tea and coffee
15:40	Lecture	Use of plasma exchange	Ashwin Pinto
16:00	Abstract	A cashier who can’t handle coins.	Dr Chinar Osman
16:15	Abstract	Case study: Neuralgic amyotrophy following hepatitis E infection	Dr Celia Shiles
16:30	AGM
17:00	Close

Queen Square Annual Update in Neuromuscular Disorders

This course will be held from Wednesday 28th May to Friday 30th May in the Clinical Neuroscience Lecture Theatre, Lower ground, 33 Queen Square, London WC1N 3B

DETAILS/REGISTRATION

Brain Fellowships

Applications are invited for 1 year fellowships funded by the Guarantors of Brain. These fellowships provide bridging salary support to early career clinicians based in the UK prior to obtaining a research fellowship. Further details can be found HERE

Hereditary Neuropathy Serine Trial

The Hereditary Sensory Neuropathy Serine trial (SENSE trial) ClinicalTrials.gov Identifier: NCT06113055

The Hereditary Sensory Neuropathy Serine trial (SENSE trial) is open to recruitment. This is a randomised double-blind placebo-controlled trial of L-serine in Hereditary Sensory Neuropathy type 1 (HSN1) due to variants in SPTLC1/2 gene.

This is a single-centre study being conducted at the National Hospital for Neurology and Neurosurgery, London UK. The Chief Investigator for this trial is Professor Mary M Reilly. If you have any affected patients who you think may interested in taking part then please invite them to contact the trial team for further information.

Recruitment will close August 2024.

New NHSE commissioning policies for rituximab and IVIg

We are pleased to announce that, largely due to the efforts of our president Prof Lunn, rituximab is now approved for treatment of IgM paraproteinaemic demyelinating peripheral neuropathy (anti-MAG phenotype, with or without anti-MAG antibodies): 1910-rituximab-for-treatment-of-PDPN-policy-v2.pdf (england.nhs.uk). Whilst we have hitherto been able to treat some patients with rituximab by sending them to a haematologist, this was not possible if the bone marrow showed insufficient evidence of underlying lymphoplasmacytic lymphoma. These patients can now be treated, regardless of bone marrow result, either by you or by your friendly haematologist, under the new commissioning guidance.
Also thanks to Prof Lunn (alongside non-neurology colleagues), the updated IVIg commissioning policy is now available: Commissioning-Criteria-Policy-for-the-use-of-Ig-Version-Finala.pdf (mdsas.com). Newly commissioned diagnoses of relevance to peripheral nerve now include acute autoimmune autonomic ganglionopathy, and neuromyotonia.
Finally, with thanks largely to the efforts of Dr Rinaldi in Oxford, rituximab can now be used for the treatment of autoimmune nodopathies (with nodal/paranodal antibodies): NHS England » Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children.

More news »

Meetings

Queen Square Annual Update in Neuromuscular Disorders

Brain Fellowships

Hereditary Neuropathy Serine Trial

New NHSE commissioning policies for rituximab and IVIg